Key facts
- It has raised $5.3M; the latest was Early Stage VC ($5.3M) in Sep 2025.
- Notable investors include Casa Verde Capital, Anthony Tabatznik, Bobby Zamora, Jay Rutland, Mark Noble.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Mamedica
- ·The full record, as it builds
Funding rounds
No funding rounds for Mamedica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mamedica
Operator of a medical cannabis clinic intended to provide safe, regulated and personalized cannabinoid therapies for patients with chronic and complex health conditions. The company offers specialist-led consultations and tailored treatment plans using medical cannabis, enabling customers to access alternative therapies that address conditions such as chronic pain, anxiety, IBS and PMDD, especially when conventional treatments have proven ineffective.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 59
- Website
- mamedica.co.uk/
- Ownership
- Privately Held (backing)
Mamedica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mamedica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mamedica in its N-PORT filings yet. We sweep new filings monthly.